Pipeline Product
ADG106
CD 137 Agonist
PD-L1
Antagonist**
Product 3 Product 4 Product 5 Product 6
  • Therapeutic Area
  • Discovery
  • PCC*
  • IND-Enabling
  • Phase Ⅰ
  • Phase Ⅱ
  1. Oncology Oncology Oncology Oncology Oncology Oncology

U.S.

China

China

Undisclosed

Undisclosed

Undisclosed

Undisclosed

*:Pre-Clinical Candidate**:Co-Development
Clinical Trials

ADG106, a fully human agonistic monoclonal antibody (mAb) targeting a novel epitope of CD137 is currently in clinical trials conducted both in China and in the US, investigating its safety in advanced and/or refractory solid tumors and lymphomas.

NameTherapeutic AreaProject
  • ADG106Advanced or Metastatic Solid Tumors and/or Non-Hodgkin LymphomaA Study of CD137 Agonist ADG106 Administered Intravenously in Patients with Advanced or Metastatic Solid Tumors and/or Non-Hodgkin Lymphoma (Protocol number: ADG106-1001)
    CLINICALTRIALS
  1. NameADG106
  2. Therapeutic AreaAdvanced or Metastatic Solid Tumors and/or Non-Hodgkin Lymphoma
  3. ProjectA Study of CD137 Agonist ADG106 Administered Intravenously in Patients with Advanced or Metastatic Solid Tumors and/or Non-Hodgkin Lymphoma (Protocol number: ADG106-1001)
    CLINICALTRIALS
Platform
The Dynamic Precision Library Platform

The Dynamic Precision Library Platform (DPL) represents a fundamental advancement in antibody discovery. The proprietary DPL libraries are designed with precision and constructed with very high fidelity. They vastly expand the druggable universe and create highly focused diversity that finely differentiates between epitopic diversity, to reach unmatched binding precision and specificity. The resulting functional antibodies consistently demonstrate uniquely favorable characteristics with differentiated product profiles.

©Copyright-Adagene 2018